Urgent.News

What's breaking now, across thousands of outlets.

More in Health & Medicine

Shionogi Grows Rare Disease Portfolio with $2B IntraBio Acquisition

Shionogi signaled its intent to focus on rare disease drugs in April when it acquired Radicava (edaravone), an amyotrophic lateral sclerosis (ALS) treatment, from Tanabe Pharma for $2.5 billion and…

  • Shionogi acquires IntraBio for $2 billion to expand rare disease portfolio.
  • Aqneursa, FDA-approved in September 2024, treats NPC and ataxia.
  • Deal subject to closing conditions, follows Radicava acquisition in April.

More from Tuesday 6 October →